By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Dompe Biogen AG Metallstrasse, 8

6300 - Zug - CH      Switzerland
Phone: 041-7287444 Fax: 041-7287440


Company News
Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting From Dompe Research For The Treatment Of Moderate To Severe Neurotrophic Keratitis Is Made In Italy 7/21/2017 7:31:20 AM
Dompe Receives Positive CHMP Opinion In Europe For Oxervate (Cenegermin Eye Drops) For The Treatment Of Adult Patients With Moderate Or Severe Neurotrophic Keratitis 5/23/2017 9:17:36 AM
Neurotrophic Keratitis: EMA Validates The Marketing Authorisation Application For Cenegermin Eye Drops (Oxervate) Submitted By Dompe 12/12/2016 8:44:05 AM
Dompe Release: Research Presented At The San Antonio Breast Cancer Symposium Intended To Strike At The Heart Of Cancer Stem Cells 12/10/2015 10:18:30 AM
Dry Eye Disease: An International Symposium By Dompé Focuses On New Research Addressing Unmet Patient Needs 9/4/2015 8:01:17 AM
Dompe Offers A New "Window" On The World Of Scientific Research, With The http://Www.Dompetrials.Com Website, Dedicated To Clinical Trials 12/17/2014 9:51:42 AM
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis 7/23/2014 12:21:27 PM
Pharmaceutical Company Dompe Launches REP0112, a Trial to Assess the Efficacy and Safety of Reparixin in Autologous Islet Cell Transplantation 9/26/2013 10:09:32 AM
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 9/11/2013 9:21:59 AM
Dompe Announces Innovative Treatment in the Fight Against Type 1 Diabetes: Pancreatic Islet Cell Transplantation, a Hope That Has Already Come True 7/11/2013 10:14:13 AM